SARS-CoV-2 spike protein-specific CD8+ T cell (Spike-specific CD8+ T cell)

CD8+ T cells specific for the SARS-CoV-2 spike protein are a specialized population of cytotoxic T lymphocytes that play a crucial role in the adaptive immune response against COVID-19 (Grifoni et al., 2020). These cells recognize viral peptides derived from the spike protein when presented on the surface of infected cells by Major Histocompatibility Complex (MHC) class I molecules (Dan et al., 2021). Upon activation, they execute targeted cell death through the secretion of perforins and granzymes, effectively limiting viral replication and spread within the host (Sahin et al., 2020). Beyond direct cytolysis, they produce key cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) to coordinate the broader immune environment. These cells are a primary target of induction for COVID-19 vaccines, including mRNA and viral vector platforms, which aim to establish long-term cellular memory to prevent severe disease (Sette & Crotty, 2021). Monitoring these cells via assays like ELISpot or multimer staining is essential for evaluating the durability of vaccine-induced immunity and the impact of emerging viral variants. Their presence is often correlated with reduced disease severity, even when neutralizing antibody titers are low. Therapeutic strategies, including vaccines and potential adoptive cell therapies, focus on maximizing the breadth and persistence of this T-cell population.

Other names

SARS-CoV-2 spike-specific CD8+ T cellsSpike-reactive cytotoxic T lymphocytesS-specific CTLsSARS-CoV-2 S-specific CD8+ T cells

Vaccine-mediated induction of antigen-specific cellular immunity via MHC class I-restricted peptide presentation and T-cell receptor activation.